(1S)-1-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1S)-1-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]ethanamine
• 化学式: C₁₄H₂₃N₃
• 分子量: 233.35
• InChiKey: KHZKQZBHJZWHPJ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• [EN] ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR<br/>[FR] INHIBITEUR DE L'ISO-CITRATE DÉSHYDROGÉNASE (IDH)
  申请人：SHANGHAI METON PHARMACEUTICAL CO LTD

  公开号：WO2018010142A1

  公开（公告）日：2018-01-18

  Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat IDH associated diseases, including cancer.

  本文披露了抑制α-KG转化为D-2-HG的化合物，以及其药用可接受的盐、水合物、溶剂合物或立体异构体，以及包含该化合物的药物组合物。该化合物和药物组合物可以有效治疗与IDH相关的疾病，包括癌症。
• Iso-citrate dehydrogenase (IDH) inhibitor
  申请人：SHANGHAI METON PHARMACEUTICAL CO., LTD

  公开号：US10752626B2

  公开（公告）日：2020-08-25

  Disclosed are compounds inhibiting the conversion of α-KG to D-2-HG pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat IDH associated diseases, including cancer.

  所公开的是抑制α-KG向D-2-HG转化的化合物及其药学上可接受的盐、水合物、溶液或立体异构体，以及包含这些化合物的药物组合物。化合物和药物组合物可以有效治疗 IDH 相关疾病，包括癌症。
• 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：Novartis AG

  公开号：EP2771337B1

  公开（公告）日：2017-08-02
• ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR
  申请人：ZHEJIANG METON PHARMACEUTICAL CO., LTD

  公开号：EP3484882B1

  公开（公告）日：2022-04-27